Esperion Therapeutics | ESPR - Pre Tax Profit


Esperion Therapeutics reported $67.66M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Amarin USD -8.12M 5.34M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cipla INR 11.69B 6.85B Dec/2025
CSL USD 1.4B 1.14B Jun/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Geron USD -18.43M 2.05M Sep/2025
Grifols EUR 66.98M 19.92M Jun/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -129M 253M Sep/2025
Merck USD 6.74B 22M Sep/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Moderna USD -187M 631M Sep/2025
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
United Therapeutics USD 438M 29.6M Sep/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024